Use of nk-1 receptor antagonists for treating movement disorders
CA 2273809 A1 · Owner: Rupniak, Nadia Melanie · Inventors: Swain, Christopher John; Hollingworth, Gregory John; Harrison, Timothy
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides the use of an orally active long acting, CNS-, penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of movement disorders methods , of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 25, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 25, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 25, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.